Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI.
This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the West, but lack the bandwidth, capital or regulatory experience to develop them for the Chinese market. The past year has seen a host of Chinese companies in-license compounds from U.S. and European biotech companies across a wide range of therapeutic areas.
Recent deal makers from the West inlcude Ambrx, Soligenix, BMG Pharma, Oncobiologics, and X-body. In early 2013, DYAX licensed Kalbitor®, a treatment for hereditary angioedema, to Lee’s Pharma Subsidiary. And, in April, Hengrui licensed X-Body’s ophthalmic therapeutic antibody generated from X-Body’s antibody platform for Age-related Macular Degeneration Antibody (AMD). Also in early 2013, OmniRat’s licensing deal with WuXi PharmaTech, MediStem and Superview’s deal to develop antibodies that affect stem cells andArGEN-X’s licensing of a cancer and anti-inflammatory mAb to RuiYi.
Recent East-West in-licensing deals involving Chinese companies:
|Jul-13||Luqa Pharaceuticals to sell BMG Pharma’s (Europe) portfoio of products|
|Jul-13||SciClone in collaboration deal with Soligenix (USA) on head and neck cancer candidate|
|Jun-13||Zhejiang Medicine gets China rights to Ambrx’s (USA) breast cancer candidate|
|May-13||Zhejiang Huahai gets rights to four biosimilars from Oncobiologics (USA)|
|Apr-13||Hengrui licenses X-Body‘s ophthalmic therapeutic antibody|
|Mar-13||Fosun Pharma will sell Saladax’s (USA) MyCare cancer assays in China|
|Feb-13||Lee’s Pharma Subsidiary In-Licenses Dyax Drug (USA)|
|Feb-13||China’s Grandhope Biotech In-licenses Stem Cell Technology from Orthocell (Australia)|
|Jan-13||SciClone continues relationship with Sanofi (Europe) surrounding four marketed therapies|
|Jan-13||Huapont Pharma and Yes Biotech (Canada) to Partner on Psoriasis Ointment|
|Jan-13||China GrandPharma In-Licenses Acetium Capsules from Biohit (Europe)|
|Jan-13||Hisun and Celsion enter into development and licensing option agreement|
|Dec-12||Techpool In-Licenses China Rights to Bone Cancer Drug from Roche (Europe)|
|Nov-12||Sihuan Pharma In-Licenses Two CCV Products from NeuroVive (Europe)|
|Oct-12||Hubei Qianjiang Pharma In-licenses Two Drugs from TNI BioTech (USA)|
|Oct-12||RuiYi In-Licenses Cancer/Anti-Inflammatory mAb from ArGEN-X (Europe)|
|Oct-12||MediStem and Superview to Develop Antibodies that affect Stem Cells|
|Sep-12||WuXi PharmaTech licenses OMT’s (USA) OmniRat to Aid Biologic Drug Discovery|
|Aug-12||Luqa Pharma In-Licenses Scar Treatment from Stratpharma (Europe)|
|Aug-12||CIBP in-licenses conjugate vaccine technology from Fina Biotech (USA)|
|Aug-12||Luqa Pharma in-licenses scar treatment from Stratpharma (Europe)
|Aug-12||PharmaEngine in-licenses cancer product from Nanobiotix (Europe)
|Jul-12||Suzhou Connect Biopharma in-licenses anti-inflammatory drugs from Arena (USA)|
|Jul-12||Lee’s Pharma in-licenses therapeutic peptide from RegeneRx (USA)|
|Jul-12||Ascletis in-licenses cancer RNAi drug from Alnylam (USA)|
The 2013 BIO® Convention in China, taking place November 11-13 in Beijing, is the best venue for cross-border business development, networking, partnering and education opportunities. Register now for the BIO® Convention in China to gain access to the BIO One-on-One Partnering™ system.